

JosÃ© Alexandre de Souza Crippa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2165013/publications.pdf>

Version: 2024-02-01

154
papers

8,074
citations

61984

43
h-index

56724

83
g-index

161
all docs

161
docs citations

161
times ranked

7695
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naïve Social Phobia Patients. <i>Neuropsychopharmacology</i> , 2011, 36, 1219-1226.	5.4	585
2	Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. <i>Current Drug Safety</i> , 2011, 6, 237-249.	0.6	422
3	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. <i>Journal of Psychopharmacology</i> , 2011, 25, 121-130.	4.0	406
4	Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 77-81.	1.4	364
5	The Psychedelic State Induced by Ayahuasca Modulates the Activity and Connectivity of the Default Mode Network. <i>PLoS ONE</i> , 2015, 10, e0118143.	2.5	308
6	Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial. <i>Journal of Psychopharmacology</i> , 2014, 28, 1088-1098.	4.0	244
7	Neuroimaging in social anxiety disorder: A systematic review of the literature. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 565-580.	4.8	242
8	Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. <i>Neuropsychopharmacology</i> , 2004, 29, 417-426.	5.4	239
9	Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. <i>Therapeutic Advances in Psychopharmacology</i> , 2016, 6, 193-213.	2.7	204
10	Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. <i>Frontiers in Immunology</i> , 2018, 9, 2009.	4.8	187
11	A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of a Translational Investigation. <i>Current Pharmaceutical Design</i> , 2012, 18, 5131-5140.	1.9	174
12	Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. <i>European Neuropsychopharmacology</i> , 2015, 25, 483-492.	0.7	145
13	Clinical validity and intrarater and test-retest reliability of the Structured Clinical Interview for DSM-5 Clinician Version (SCID-5/CV). <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 754-760.	1.8	145
14	Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. <i>Brain Research</i> , 2011, 1388, 167-177.	2.2	142
15	Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 56-61.	1.7	121
16	Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa. <i>CNS and Neurological Disorders - Drug Targets</i> , 2014, 13, 953-960.	1.4	116
17	Assessing the Psychedelic "After-Glow" in Ayahuasca Users: Post-Acute Neurometabolic and Functional Connectivity Changes Are Associated with Enhanced Mindfulness Capacities. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 698-711.	2.1	111
18	Cannabidiol as a Promising Strategy to Treat and Prevent Movement Disorders?. <i>Frontiers in Pharmacology</i> , 2018, 9, 482.	3.5	110

#	ARTICLE	IF	CITATIONS
19	Patterns of regional gray matter loss at different stages of schizophrenia: A multisite, cross-sectional VBM study in first-episode and chronic illness. <i>NeuroImage: Clinical</i> , 2016, 12, 1-15.	2.7	107
20	Factor Structure, Reliability, and Item Parameters of the Brazilian-Portuguese Version of the GAD-7 Questionnaire. <i>Temas Em Psicologia</i> , 2016, 24, 367-376.	0.3	101
21	Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 65-72.	1.7	98
22	Comparability Between Telephone and Face-to-Face Structured Clinical Interview for DSM-IV in Assessing Social Anxiety Disorder. <i>Perspectives in Psychiatric Care</i> , 2008, 44, 241-247.	1.9	96
23	Association Between Physician Depressive Symptoms and Medical Errors. <i>JAMA Network Open</i> , 2019, 2, e1916097.	5.9	88
24	Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2013, 38, 162-164.	1.5	82
25	Classical hallucinogens and neuroimaging: A systematic review of human studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2016, 71, 715-728.	6.1	79
26	Interaction between cannabidiol (CBD) and Δ^9 -tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids. <i>Psychopharmacology</i> , 2012, 219, 247-249.	3.1	78
27	No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. <i>Frontiers in Pharmacology</i> , 2018, 9, 315.	3.5	70
28	Are cavum septum pellucidum abnormalities more common in schizophrenia spectrum disorders? A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2011, 125, 1-12.	2.0	69
29	Cannabidiol Normalizes Caspase 3, Synaptophysin, and Mitochondrial Fission Protein DNM1L Expression Levels in Rats with Brain Iron Overload: Implications for Neuroprotection. <i>Molecular Neurobiology</i> , 2014, 49, 222-233.	4.0	69
30	Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease. <i>Journal of Psychopharmacology</i> , 2020, 34, 189-196.	4.0	69
31	Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. <i>Brain Research</i> , 2019, 1715, 156-164.	2.2	67
32	Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. <i>Journal of Psychoactive Drugs</i> , 2016, 48, 195-205.	1.7	65
33	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	1.7	64
34	Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. <i>Journal of Psychopharmacology</i> , 2013, 27, 312-316.	4.0	64
35	Structural magnetic resonance imaging in anxiety disorders: an update of research findings. <i>Revista Brasileira De Psiquiatria</i> , 2008, 30, 251-264.	1.7	63
36	Social anxiety disorder women easily recognize fearful, sad and happy faces: The influence of gender. <i>Journal of Psychiatric Research</i> , 2010, 44, 535-540.	3.1	62

#	ARTICLE	IF	CITATIONS
37	Phytocannabinoids and epilepsy. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 135-143.	1.5	60
38	Î”9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol. <i>Frontiers in Pharmacology</i> , 2016, 7, 359.	3.5	60
39	Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. <i>Frontiers in Pharmacology</i> , 2014, 5, 10.	3.5	59
40	Social phobia in Brazilian university students: Prevalence, under-recognition and academic impairment in women. <i>Journal of Affective Disorders</i> , 2012, 136, 857-861.	4.1	57
41	Protective Effects of Cannabidiol against Seizures and Neuronal Death in a Rat Model of Mesial Temporal Lobe Epilepsy. <i>Frontiers in Pharmacology</i> , 2017, 8, 131.	3.5	56
42	The prevalence and clinical correlates of cannabis use and cannabis use disorder among patients with bipolar disorder: A systematic review with meta-analysis and meta-regression. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 101, 78-84.	6.1	51
43	Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload. <i>Translational Psychiatry</i> , 2018, 8, 176.	4.8	50
44	Cavum septum pellucidum and adhesio interthalamica in schizophrenia: an MRI study. <i>European Psychiatry</i> , 2006, 21, 291-299.	0.2	47
45	A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans. <i>Cannabis and Cannabinoid Research</i> , 2017, 2, 81-86.	2.9	47
46	Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic. <i>JAMA Network Open</i> , 2021, 4, e2120603.	5.9	47
47	Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1264, 29-45.	1.6	47
48	Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. <i>Revista Brasileira De Psiquiatria</i> , 2012, 34, S104-S117.	1.7	47
49	Cannabidiol Prevents Motor and Cognitive Impairments Induced by Reserpine in Rats. <i>Frontiers in Pharmacology</i> , 2016, 7, 343.	3.5	46
50	Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 517-526.	3.3	46
51	Recent advances in LC-MS/MS methods to determine endocannabinoids in biological samples: Application in neurodegenerative diseases. <i>Analytica Chimica Acta</i> , 2018, 1044, 12-28.	5.4	43
52	Is cannabidiol the ideal drug to treat non-motor Parkinson’s disease symptoms?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 121-133.	3.2	41
53	Adhesio interthalamica alterations in schizophrenia spectrum disorders: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 877-886.	4.8	40
54	Cross- cultural validation of the Brazilian Portuguese version of the Social Phobia Inventory (SPIN): study of the items and internal consistency. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 25-29.	1.7	39

#	ARTICLE	IF	CITATIONS
55	Novel insights into mitochondrial molecular targets of iron-induced neurodegeneration: Reversal by cannabidiol. <i>Brain Research Bulletin</i> , 2018, 139, 1-8.	3.0	38
56	Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System. <i>CNS Drugs</i> , 2018, 32, 697-712.	5.9	37
57	Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats. <i>Frontiers in Pharmacology</i> , 2017, 8, 391.	3.5	36
58	Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia. <i>Frontiers in Pharmacology</i> , 2018, 9, 901.	3.5	36
59	Further psychometric study of the Beck Anxiety Inventory including factorial analysis and social anxiety disorder screening. <i>International Journal of Psychiatry in Clinical Practice</i> , 2011, 15, 255-262.	2.4	35
60	Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. <i>PLoS ONE</i> , 2016, 11, e0158779.	2.5	35
61	Determination of Drugs in Plasma Samples by High-Performance Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring of Schizophrenic Patients. <i>Journal of Analytical Toxicology</i> , 2016, 40, bkv107.	2.8	34
62	In-tube solid-phase microextraction with a dummy molecularly imprinted monolithic capillary coupled to ultra-performance liquid chromatography-tandem mass spectrometry to determine cannabinoids in plasma samples. <i>Analytica Chimica Acta</i> , 2020, 1099, 145-154.	5.4	34
63	A column switching ultrahigh-performance liquid chromatography-tandem mass spectrometry method to determine anandamide and 2-arachidonoylglycerol in plasma samples. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 3587-3596.	3.7	33
64	DMH-CBD, a cannabidiol analog with reduced cytotoxicity, inhibits TNF production by targeting NF-κB activity dependent on A2A receptor. <i>Toxicology and Applied Pharmacology</i> , 2019, 368, 63-71.	2.8	33
65	Evaluation of the psychometric properties of the Social Phobia Inventory in university students. <i>Comprehensive Psychiatry</i> , 2010, 51, 630-640.	3.1	32
66	Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (<i>Danio rerio</i>). <i>Pharmacology Biochemistry and Behavior</i> , 2015, 135, 210-216.	2.9	32
67	Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits. <i>Neuroscience</i> , 2017, 350, 85-93.	2.3	32
68	Cannabidiol Exposure During Neuronal Differentiation Sensitizes Cells Against Redox-Active Neurotoxins. <i>Molecular Neurobiology</i> , 2015, 52, 26-37.	4.0	30
69	Oral Cannabidiol Does Not Convert to Δ^8 -THC or Δ^9 -THC in Humans: A Pharmacokinetic Study in Healthy Subjects. <i>Cannabis and Cannabinoid Research</i> , 2020, 5, 89-98.	2.9	30
70	Cannabidiol did not induce teratogenicity or neurotoxicity in exposed zebrafish embryos. <i>Chemico-Biological Interactions</i> , 2018, 291, 81-86.	4.0	29
71	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5): transcultural adaptation of the Brazilian version. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 10-19.	0.6	28
72	Neuroimaging of major depression in Parkinson's disease: Cortical thickness, cortical and subcortical volume, and spectroscopy findings. <i>Journal of Psychiatric Research</i> , 2017, 90, 40-45.	3.1	27

#	ARTICLE	IF	CITATIONS
73	Cannabidiol induces antidepressant and anxiolytic-like effects in experimental type-1 diabetic animals by multiple sites of action. <i>Metabolic Brain Disease</i> , 2021, 36, 639-652.	2.9	27
74	Evaluation of the Psychometric Properties of the Cognitive Distortions Questionnaire (CD-Quest) in a Sample of Undergraduate Students. <i>Innovations in Clinical Neuroscience</i> , 2015, 12, 20-7.	0.1	27
75	Neuroimaging of depression in Parkinson's disease: a review. <i>International Psychogeriatrics</i> , 2013, 25, 1953-1961.	1.0	26
76	Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study. <i>Revista Brasileira De Psiquiatria</i> , 2021, 43, 467-476.	1.7	26
77	Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531984577.	2.7	25
78	Dissociation between the panicolytic effect of cannabidiol microinjected into the substantia nigra, pars reticulata, and fear-induced antinociception elicited by bicuculline administration in deep layers of the superior colliculus: The role of CB1-cannabinoid receptor in the ventral mesencephalon. <i>European Journal of Pharmacology</i> , 2015, 758, 153-163.	3.5	24
79	Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy. <i>Frontiers in Pharmacology</i> , 2016, 7, 303.	3.5	24
80	Facial emotion recognition in social anxiety: The influence of dynamic information.. <i>Psychology and Neuroscience</i> , 2016, 9, 1-11.	0.8	24
81	Sub-chronic treatment with cannabidiol but not with URB597 induced a mild antidepressant-like effect in diabetic rats. <i>Neuroscience Letters</i> , 2018, 682, 62-68.	2.1	23
82	Risk and Protective Factors for the Mental Health of Brazilian Healthcare Workers in the Frontline of COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2021, 12, 662742.	2.6	23
83	Escala para auto-avaliação ao falar em público (SSPS): adaptação transcultural e consistência interna da versão brasileira. <i>Revista De Psiquiatria Clinica</i> , 2008, 35, 207-211.	0.6	23
84	Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia. <i>Schizophrenia Research</i> , 2016, 172, 220-221.	2.0	22
85	Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 658-669.	2.9	22
86	The Fast Alcohol Screening Test (FAST) is as Good as the AUDIT to Screen Alcohol Use Disorders. <i>Substance Use and Misuse</i> , 2010, 45, 1542-1557.	1.4	21
87	Olanzapine, weight change and metabolic effects: a naturalistic 12-month follow up. <i>Therapeutic Advances in Psychopharmacology</i> , 2014, 4, 30-36.	2.7	21
88	Magnetic resonance spectroscopy in anxiety disorders. <i>Acta Neuropsychiatrica</i> , 2008, 20, 56-71.	2.1	20
89	Clinical issues in cannabis use. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 2495-2498.	2.4	20
90	Facial emotion processing in patients with social anxiety disorder and Williams-Beuren syndrome: an fMRI study. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, 182-191.	2.4	20

#	ARTICLE	IF	CITATIONS
91	Further Study of the Psychometric Qualities of a Brief Screening Tool for Social Phobia (MINI-SPIN) Applied to Clinical and Nonclinical Samples. <i>Perspectives in Psychiatric Care</i> , 2010, 46, 266-278.	1.9	19
92	Biological bases for a possible effect of cannabidiol in Parkinson's disease. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 218-224.	1.7	18
93	The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 1-10.	2.9	17
94	Epigenetic variation at the SLC6A4 gene promoter in mother-child pairs with major depressive disorder. <i>Journal of Affective Disorders</i> , 2019, 245, 716-723.	4.1	17
95	Two-weeks treatment with cannabidiol improves biophysical and behavioral deficits associated with experimental type-1 diabetes. <i>Neuroscience Letters</i> , 2020, 729, 135020.	2.1	16
96	Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit. <i>Neuropharmacology</i> , 2019, 155, 44-53.	4.1	15
97	Are there differences between early- and late-onset social anxiety disorder?. <i>Revista Brasileira De Psiquiatria</i> , 2007, 29, 195-196.	1.7	15
98	Cannabis sativa: a planta que pode produzir efeitos indesejáveis e também tratá-los. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 51-52.	1.7	15
99	Effects of cannabidiol on symptoms induced by the recall of traumatic events in patients with posttraumatic stress disorder. <i>Psychopharmacology</i> , 2022, 239, 1499-1507.	3.1	15
100	Agomelatine in the treatment of social anxiety disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 1357-1358.	4.8	14
101	Modulation of the Endocannabinoid and Oxytocinergic Systems as a Potential Treatment Approach for Social Anxiety Disorder. <i>CNS Drugs</i> , 2019, 33, 1031-1038.	5.9	14
102	Ensuring access to safe, effective, and affordable cannabis-based medicines. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 630-634.	2.4	14
103	Aspectos cognitivos do falar em público: validação de uma escala de autoavaliação para universitários brasileiros. <i>Revista De Psiquiatria Clínica</i> , 2012, 39, 48-53.	0.6	13
104	Cannabidiol and endogenous opioid peptide-mediated mechanisms modulate antinociception induced by transcutaneous electrostimulation of the peripheral nervous system. <i>Journal of the Neurological Sciences</i> , 2014, 347, 82-89.	0.6	13
105	Mental health in medical residents: relationship with personal, work-related, and sociodemographic variables. <i>Revista Brasileira De Psiquiatria</i> , 2016, 38, 318-324.	1.7	13
106	Endocannabinoid levels in patients with Parkinson's disease with and without levodopa-induced dyskinesias. <i>Journal of Neural Transmission</i> , 2020, 127, 1359-1367.	2.8	13
107	Does social phobia remain the 'Ugly Duckling' of anxiety disorders?. <i>Revista Brasileira De Psiquiatria</i> , 2009, 31, 297-299.	1.7	13
108	Instituto Nacional de Ciência e Tecnologia em Medicina Translacional (INCT-TM): abordagens metodológicas. <i>Revista Brasileira De Psiquiatria</i> , 2010, 32, 83-90.	1.7	13

#	ARTICLE	IF	CITATIONS
109	Cannabidiol as a Treatment for Mental Health Outcomes Among Health Care Workers During the Coronavirus Disease Pandemic. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 327-329.	1.4	12
110	Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1076.	4.1	12
111	Electrodermally Nonresponsive Schizophrenia Patients Make More Errors in the Stroop Color Word Test, Indicating Selective Attention Deficit. <i>Schizophrenia Bulletin</i> , 2002, 28, 459-466.	4.3	11
112	Cross-cultural validation of the Brief Social Phobia Scale for use in Portuguese and the development of a structured interview guide. <i>Revista Brasileira De Psiquiatria</i> , 2006, 28, 212-217.	1.7	11
113	Personality Inventory for DSM-5 (PID-5): cross-cultural adaptation and content validity in the Brazilian context. <i>Trends in Psychiatry and Psychotherapy</i> , 2019, 41, 297-300.	0.8	11
114	The anxiolytic effect of cannabidiol depends on the nature of the trauma when patients with post-traumatic stress disorder recall their trigger event. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 298-307.	1.7	11
115	Utilização do Inventário de Habilidades sociais no diagnóstico do Transtorno de Ansiedade Social. <i>Psicologia: Reflexão E Crítica</i> , 2012, 25, 467-476.	0.9	10
116	Heritability of social anxiety disorder: a systematic review of methodological designs. <i>Revista De Psiquiatria Clinica</i> , 2016, 43, 83-92.	0.6	10
117	Psychometric properties of the dimensional anxiety scales for DSM-5 in a Brazilian community sample. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	2.1	10
118	Early interventions for the prevention of PTSD in adults: a systematic literature review. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 23-29.	0.6	10
119	Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 970-978.	1.4	10
120	Intraperitoneal cannabidiol attenuates neonatal germinal matrix hemorrhage-induced neuroinflammation and perilesional apoptosis. <i>Neurological Research</i> , 2019, 41, 980-990.	1.3	9
121	The effects of Cannabidiol (CBD) and Delta-9-Tetrahydrocannabinol (THC) on the recognition of emotions in facial expressions: A systematic review of randomized controlled trials. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 118, 236-246.	6.1	9
122	Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification. <i>Schizophrenia Research</i> , 2021, 236, 104-114.	2.0	9
123	Possible Interactions Between 5-HT2A Receptors and the Endocannabinoid System in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 644-646.	1.4	8
124	Cannabidiol-induced panicolytic-like effects and fear-induced antinociception impairment: the role of the CB1 receptor in the ventromedial hypothalamus. <i>Psychopharmacology</i> , 2020, 237, 1063-1079.	3.1	8
125	Case Report: Cannabidiol-Induced Skin Rash: A Case Series and Key Recommendations. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	8
126	Effect of two oral formulations of cannabidiol on responses to emotional stimuli in healthy human volunteers: pharmaceutical vehicle matters. <i>Revista Brasileira De Psiquiatria</i> , 2022, 44, 15-20.	1.7	7

#	ARTICLE	IF	CITATIONS
127	Monitoring the Mental Health and Professional Overload of Health Workers in Brazil: A Longitudinal Study Considering the First Wave of the COVID-19 Pandemic. <i>Frontiers in Psychiatry</i> , 2022, 13, 852157.	2.6	7
128	Lipoma adhered to the corpus callosum in a schizophrenic patient with severe positive symptoms that responded to clozapine. <i>Acta Neuropsychiatrica</i> , 2002, 14, 36-38.	2.1	5
129	Anxiety, panic, and hopelessness during and after ritual ayahuasca intake in a woman with generalized anxiety disorder: A case report. <i>Journal of Psychedelic Studies</i> , 2017, 1, 35-39.	1.2	5
130	Can anxiety increase tremors in patients with Parkinson's disease? An experimental model. <i>Revista De Psiquiatria Clinica</i> , 2017, 44, 85-88.	0.6	5
131	Borderline personality disorder and bias in the recognition of facial expressions of emotion: a pathway to understand the psychopathology. <i>Revista De Psiquiatria Clinica</i> , 2018, 45, 7-11.	0.6	5
132	The Effect of Cannabidiol for Restless Legs Syndrome/Willis-Ekbom Disease in Parkinson's Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2/3 Clinical Trial. <i>Cannabis and Cannabinoid Research</i> , 0, , .	2.9	4
133	Cross-cultural adaptation and psychometric assessment of a Brazilian-Portuguese version of the Resident Questionnaire. <i>PLoS ONE</i> , 2018, 13, e0203531.	2.5	3
134	O uso do canabidiol (CBD) no tratamento da doença de Parkinson e suas comorbidades. , 2019, 98, 46-51.	0.1	3
135	A single oral dose of cannabidiol did not reduce upper limb tremor in patients with essential tremor. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 37-40.	2.2	3
136	Cannabidiol reverses memory impairments and activates components of the Akt/GSK3 β pathway in an experimental model of estrogen depletion. <i>Behavioural Brain Research</i> , 2021, 417, 113555.	2.2	3
137	Social Anxiety Disorder, Fear of Public Speaking, and the use of Assessment Instruments. , 0, , .		2
138	Transtorno de ansiedade social e habilidades sociais de falar em público: estudo experimental. <i>Estudos E Pesquisas Em Psicologia</i> , 2012, 12, .	0.1	2
139	Harmine impairs memory performance of treated rats and nontreated cagemates.. <i>Experimental and Clinical Psychopharmacology</i> , 2022, 30, 751-759.	1.8	2
140	Assessment of referrals to an OT consultation-liaison service: a retrospective and comparative study. <i>Scandinavian Journal of Occupational Therapy</i> , 2012, 19, 84-91.	1.7	1
141	Disability Profile/Clinician-Rated: Validity for Brazilian University Students with Social Anxiety Disorder. <i>Spanish Journal of Psychology</i> , 2013, 16, E48.	2.1	1
142	Editorial (Thematic Issue: Translational Neuroscience: Narrowing Distances for Future Discoveries). <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 962-962.	1.4	1
143	Letter to the Editor. <i>Journal of Clinical Forensic and Legal Medicine</i> , 2016, 38, 116-117.	1.0	1
144	17.4 POSSIBLE MECHANISMS INVOLVED IN THE ANTIPSYCHOTIC EFFECTS OF CANNABIDIOL (CBD). <i>Schizophrenia Bulletin</i> , 2018, 44, S28-S28.	4.3	1

#	ARTICLE	IF	CITATIONS
145	Proneness, urbanicity, trauma, and cannabis triggering psychotic states in large urban centers. Current Opinion in Psychiatry, 2020, 33, 250-254.	6.3	1
146	Memory Bias and Personality Characteristics in College Students with Social Anxiety Disorder. Trends in Psychiatry and Psychotherapy, 2021, , .	0.8	1
147	Arthur Bispo do Rosário (1909?-1989): Insanity and Art. American Journal of Psychiatry, 2009, 166, 1117-1117.	7.2	0
148	Structural imaging of other anxiety disorders. , 0, , 274-287.		0
149	False memories in social anxiety disorder. Revista De Psiquiatria Clinica, 2017, 44, 113-116.	0.6	0
150	Prof. Elisaldo Araújo Carlini, Cannabis and Cannabinoids Research Pioneer (June 9, 1930â€“September 16,) Tj ETQg0,0 0 rgBT /Overlock	2.9	0
151	The first department of medical psychology in the world and its impact on medical education. Revista Brasileira De Psiquiatria, 2021, , .	1.7	0
152	Increased body sway in phobic patients exposed to images of spiders. Revista Brasileira De Psiquiatria, 2021, 43, 477-483.	1.7	0
153	Circulating Endocannabinoids in Huntingtonâ€™s Disease: An Exploratory Cross-Sectional Study. Journal of Huntington's Disease, 2022, , 1-5.	1.9	0
154	Is it the Ideal Time to Start Prescribing Cannabis Derivatives to Treat Endometriosis-associated Pain?. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 449-451.	0.8	0